In the previous post, we covered the two structural criteria that most reliably distinguish a translational development partner from a contract manufacturer: modality-specific...
Read More →July 06, 2026
In the first post in this series, we looked at the manufacturing landscape for advanced therapies and what the FDA data tells us...
Read more →April 27, 2026
At Advanced Therapies Week 2026, our Chief Technology Officer, Gregg Nyberg, joined a panel of industry leaders to discuss how...
Read more →April 02, 2026
Your science is ready.
The mechanism is well-characterized, the preclinical data is compelling, and the clinical development...
Read more →